Autosomal recessive hypophosphatemic rickets

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:289176OMIM:241520E83.3
Who is this for?
Show terms as
3Active trials4Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Autosomal recessive hypophosphatemic rickets (ARHR) is a rare inherited bone disorder caused by the body's inability to properly manage phosphate, an essential mineral needed for strong and healthy bones and teeth. In this condition, the kidneys lose too much phosphate into the urine, leading to low phosphate levels in the blood (hypophosphatemia). Without enough phosphate, bones cannot mineralize properly, which means they become soft and weak. Children with ARHR typically develop signs of rickets, including bowed legs or knock knees, short stature, bone pain, and dental problems such as tooth abscesses. The condition usually becomes apparent in early childhood when a child begins to walk and bear weight on their legs. Some patients may also experience muscle weakness and difficulty walking. Treatment focuses on replacing phosphate and active vitamin D (calcitriol) to improve bone mineralization and support normal growth. With early diagnosis and consistent treatment, many of the skeletal problems can be improved or prevented. Regular monitoring by specialists is important to adjust treatment doses and watch for complications such as kidney calcification (nephrocalcinosis). In some cases, surgical correction of bone deformities may be needed. ARHR is sometimes also referred to as autosomal recessive vitamin D-resistant rickets type 1 or type 2, depending on the gene involved.

Also known as:

Key symptoms:

Bowed legs or knock kneesShort stature or poor growthBone painMuscle weaknessDifficulty walking or waddling gaitDelayed walking milestonesFrequent dental abscesses or tooth decaySoft or fragile bones that fracture easilyWidening of the wrists or anklesBone deformities of the legsFatigue or low energyDelayed closure of the skull's soft spots (fontanelles)Poor dental enamel

Clinical phenotype terms (37)— hover any for plain English
Hypophosphatemic ricketsHP:0004912Renal phosphate wastingHP:0000117OsteomalaciaHP:0002749Enlargement of the wristsHP:0003020HyperphosphaturiaHP:0003109Sclerotic vertebral endplatesHP:0004576Distal femoral bowingHP:0005096Polyarticular arthritisHP:0005764Rickets of the lower limbsHP:0006463Renal hypophosphatemiaHP:0008732Elevated alkaline phosphatase of bone originHP:0010639
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

4 events
Mar 2025ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency

Inozyme Pharma — PHASE3

TrialRECRUITING
Jul 2024PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

Inozyme Pharma

TrialRECRUITING
Nov 2023The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Inozyme Pharma — PHASE3

TrialACTIVE NOT RECRUITING
Jun 2023The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

Inozyme Pharma — PHASE1

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Autosomal recessive hypophosphatemic rickets.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 32 trials
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency
Phase 3
Actively Recruiting
PI: Medical Director, MD (BioMarin Pharmaceutical) · Sites: Rio de Janeiro; Paris +6 more · Age: 01 yrs
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Phase 3
Active
PI: Kurt Gunter, MD (Inozyme Pharma, Inc.) · Sites: Aurora, Colorado; Chicago, Illinois +13 more · Age: 112 yrs
Phase 11 trial
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
Phase 1
Actively Recruiting
PI: Medical Director, MD, MD (BioMarin Pharmaceutical) · Sites: San Diego, California; Boston, Massachusetts +5 more · Age: 01 yrs

Specialists

4 foundView all specialists →
PM
Pedro Huertas, MD
CONCORD, MA
Specialist
PI on 1 active trial
CM
Carlos R Ferreira Lopez, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 2 active trials
AM
Alex Lai, MD
Specialist
PI on 1 active trial1 Autosomal recessive hypophosphatemic rickets publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Autosomal recessive hypophosphatemic rickets.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Autosomal recessive hypophosphatemic ricketsForum →

No community posts yet. Be the first to share your experience with Autosomal recessive hypophosphatemic rickets.

Start the conversation →

Latest news about Autosomal recessive hypophosphatemic rickets

Disease timeline:

New recruiting trial: PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

A new clinical trial is recruiting patients for Autosomal recessive hypophosphatemic rickets

New recruiting trial: ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency

A new clinical trial is recruiting patients for Autosomal recessive hypophosphatemic rickets

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which gene is causing my child's condition, and does that affect the treatment plan?,How often will my child need blood tests, urine tests, and kidney ultrasounds to monitor treatment?,What are the signs that the phosphate or vitamin D dose needs to be adjusted?,Is burosumab (Crysvita) an option for my child's specific type of ARHR?,At what point should we consider orthopedic surgery for leg bowing?,What dental precautions should we take to prevent abscesses and tooth problems?,Should other family members be tested to see if they are carriers?

Common questions about Autosomal recessive hypophosphatemic rickets

What is Autosomal recessive hypophosphatemic rickets?

Autosomal recessive hypophosphatemic rickets (ARHR) is a rare inherited bone disorder caused by the body's inability to properly manage phosphate, an essential mineral needed for strong and healthy bones and teeth. In this condition, the kidneys lose too much phosphate into the urine, leading to low phosphate levels in the blood (hypophosphatemia). Without enough phosphate, bones cannot mineralize properly, which means they become soft and weak. Children with ARHR typically develop signs of rickets, including bowed legs or knock knees, short stature, bone pain, and dental problems such as too

How is Autosomal recessive hypophosphatemic rickets inherited?

Autosomal recessive hypophosphatemic rickets follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Autosomal recessive hypophosphatemic rickets typically begin?

Typical onset of Autosomal recessive hypophosphatemic rickets is childhood. Age of onset can vary across affected individuals.

Are there clinical trials for Autosomal recessive hypophosphatemic rickets?

Yes — 3 recruiting clinical trials are currently listed for Autosomal recessive hypophosphatemic rickets on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Autosomal recessive hypophosphatemic rickets?

4 specialists and care centers treating Autosomal recessive hypophosphatemic rickets are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.